Metsera (NASDAQ:MTSR) Hits New 12-Month Low – What’s Next?

Metsera, Inc. (NASDAQ:MTSR) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $24.11 and last traded at $24.57, with a volume of 131556 shares trading hands. The stock had previously closed at $25.03.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Guggenheim assumed coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 target price for the company. Evercore ISI started coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating on the stock. Cantor Fitzgerald started coverage on Metsera in a report on Tuesday, February 25th. They set an “overweight” rating for the company. Finally, Bank of America initiated coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target for the company.

Metsera Stock Down 5.9 %

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.